Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials

• Published in: Tumor biology Vol. 37; no. 5; pp. 6297 - 6306
• Main Authors: Li, Yan, Liang, Xin-Yue, Yue, Yi-Qi, Sheng, Lei, Liu, Ji-Kai, Wang, Zhan-Yu, Chen, Gang
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.05.2016; Springer Nature B.V
• Subjects: Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab - administration & dosage; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Chemotherapy; Clinical trials; Growth factors; Humans; Meta-analysis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Original Article; Protein Kinase Inhibitors - administration & dosage; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-1 - genetics; Chemotherapy; Anti-VEGF/VEGFR drugs; Complete response; Meta-analysis

Drugs targeting the vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling (anti-VEGF/VEGFR drugs) are the most validated anti-angiogenic strategies for cancer treatment. Complete response (CR) is a rare event in cancer patients receiving chemotherapy. A meta-analysis was condu...